The information presented here reflects the consensus emerging from user communities, peptide researchers, and practitioners familiar with these compounds
According to the **TRIUMPH-1 Phase 3 trial results published by Eli Lilly in May 2026**, Retatrutide at the 12mg maintenance dose produced an average of 28.3% body weight reduction over 80 weeks
Schmieder received grants to the institution from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim and NovoNordisk and speaker and advisor honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk , Servier and TAD Christoph Wanner has received grants and served on steering committees for Boehringer Ingelheim
The condition reduces facial volume because of subcutaneous fat loss, creating a hollowed look with sunken features alongside deeper wrinkles and skin that sags